- Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer
FengLi Wang et al, 2021, Expert Review of Clinical Pharmacology CrossRef - The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Jong Hyun Choi et al, 2019, Tuberculosis and Respiratory Diseases CrossRef - Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial
Cheol-Kyu Park et al, 2017, Clinical Lung Cancer CrossRef - A review of relative dose intensity and survival in patients with metastatic solid tumors
Laura J. Havrilesky et al, 2015, Critical Reviews in Oncology/Hematology CrossRef - Efficacy and safety of docetaxel plus oxaliplatin as a first‐line chemotherapy in patients with advanced or metastatic non‐small cell lung cancer
Heejung Ban et al, 2014, Thoracic Cancer CrossRef - Phase I Dose-Escalation Study of Aflibercept Plus Docetaxel in Nasopharyngeal Carcinoma and Other Solid Tumors
Yan Huang et al, 2014, Future Oncology CrossRef - Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
K Shitara et al, 2014, British Journal of Cancer CrossRef